Q32 Reports Positive Mid-Stage Results for Alopecia Areata Therapy

Rare Daily Staff

Q32 Bio reported positive mid-stage clinical trial results for its experimental drug bempikibart in people with alopecia areata, an autoimmune condition that causes hair loss.

In a 36-week phase 2 study involving patients with severe disease, the treatment led to meaningful hair regrowth. On average, patients experienced a 35 percent improvement in scalp hair coverage. About 40 percent of participants achieved substantial regrowth—defined as at least 80 percent scalp coverage—based on an analysis of treated patients. Results were somewhat lower, but still notable, when all enrolled patients were included.

Alopecia areata can have a significant emotional and psychological impact. While newer treatments such as JAK inhibitors are available, they may not work for all patients and can carry safety concerns. Bempikibart takes a different approach by targeting immune signaling pathways believed to drive the disease, potentially offering an alternative option.

The drug was generally well tolerated in the trial, with no serious safety issues reported. The most common side effect was mild injection-site reactions. Researchers also observed early signs that the treatment’s benefits may persist after discontinuation, although longer follow-up is ongoing.

Q32 Bio plans to advance bempikibart into larger, late-stage trials aimed at regulatory approval starting in the first half of 2027. Additional data from the current study are expected to be presented at a future medical meeting.

Experts say the findings are promising, particularly for patients who have already tried existing therapies. If confirmed in larger studies, bempikibart could become a new option in a space where treatment choices remain limited.

“These results provide further evidence that our differentiated approach to targeting the biology underlying alopecia areata has the potential to translate into meaningful and durable clinical benefit for patients,” said Shelia Violette, co-founder and chief scientific officer of Q32 Bio. “Despite recent advances, many patients continue to seek treatment options that combine robust efficacy with improved safety and the potential for sustained disease control. These findings strengthen our confidence in this mechanism and support its continued advancement as a differentiated treatment option for patients living with alopecia areata and other autoimmune and inflammatory diseases.”